Large-scale testing (Phase 3)Study completedNCT02699099
What this trial is testing
Immunogenicity and Safety Study of GSK Biologicals' Candidate Malaria Vaccine Given at 6, 7.5 and 9 Months of Age in Co-administration With Measles, Rubella and Yellow Fever (YF) Vaccines Followed by a Booster of the Malaria Vaccine.
Who this might be right for
MalariaMalaria Vaccines
GlaxoSmithKline 699